ReviewNature reviews. Rheumatology2013
Management of cancer treatment-induced bone loss.
Review in Nature reviews. Rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The Effect of Exercise and Nutritional Interventions on Body Composition in Patients with Advanced or Metastatic Cancer: A Systematic Review.Nutrients · 2022Pooled it
- Pooled it
- Guidelines for the management of osteoporosis and fragility fractures.Internal and emergency medicine · 2019Guideline
- Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.Journal of general internal medicine · 2016Pooled it
- A Randomized Controlled Trial of Exercise to Prevent Bone Loss in Premenopausal Women with Breast Cancer.Journal of women's health (2002) · 2019Trial
- FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment.The Journal of clinical endocrinology and metabolism · 2016Trial
- Activation of the noncanonical inflammasome-GSDMD pathway triggers pyroptosis in bone marrow and promotes periosteal bone formation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Bone Health in Breast Cancer Patients: Comparative Evaluation Using Dual Energy X-Ray Absorptiometry Scan and High-Resolution Peripheral Quantitative Computed Tomography.Journal of bone metabolism · 2026Article
- Activation of the noncanonical inflammasome-GSDMD pathway triggers pyroptosis in bone marrow and promotes periosteal bone formation.bioRxiv : the preprint server for biology · 2025Article
- Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases.Journal of clinical medicine · 2025Article
- Trend and Cancer-Specific Prevalence of Kidney Stones Among US Cancer Survivors, 2007-2020.Current oncology (Toronto, Ont.) · 2025Article
- Targeted delivery of liposomal senolytics to alleviate cellular senescence-induced bone loss.Fundamental research · 2025Article
- Osteopenic occult vertebral fracture is associated with poor oncological outcome in patients with hepatocellular carcinoma after hepatic resection.Annals of gastroenterological surgery · 2025Article
- Chemotherapy effects on bone mineral density and microstructure in women with breast cancer.Journal of bone and mineral metabolism · 2024Observational
- Article
- Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles.Nanomedicine (London, England) · 2024Article
- Article
- Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy.Journal of bone and mineral metabolism · 2023Article
- Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancer.Archives of osteoporosis · 2023Article
- Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis.Journal of experimental & clinical cancer research : CR · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The survival prospects for many patients with cancer are steadily improving. As a result, survivorship issues are of increasing importance as attempts are made to minimize the long-term adverse effects of cancer treatments. Cancer therapies can adversely affect bone health, particularly in women with breast cancer and men with prostate cancer. Strategies for screening patients at increased risk for fragility fracture, and treatment algorithms using both bone-targeted treatments and other therapeutic interventions, are being developed. Both bisphosphonates and denosumab have been evaluated as treatments to prevent or reverse the bone loss associated with cancer treatments. Zoledronic acid is the most extensively assessed agent and has been shown to prevent bone loss in patients with breast cancer experiencing a premature menopause, in postmenopausal women receiving an aromatase inhibitor and in patients with prostate cancer undergoing androgen deprivation therapy (ADT). To date, the improvements in bone mineral density have not translated into a reduced fracture rate. However, in a large phase III trial, denosumab has been shown to reduce vertebral fractures in men receiving ADT for prostate cancer. These bone-targeted treatments have also been shown to modify the course of the underlying cancer and prevent metastasis, although the beneficial effects are confined to patients with low levels of circulating reproductive hormones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.